Abstract
The tumor-derived fraction of circulating cell-free DNA (cfDNA) in various body fluids, known as circulating tumor DNA (ctDNA), can serve as a minimally invasive tumor biomarker. Artificial intelligence (AI) using next-generation sequencing data promises to revolutionize assay performance and its integration into the clinical workflow to advance precision medicine. AI and machine learning-based ctDNA profiling, including epigenetic profiling, may assist early-stage detection and prediction of cancer progression, helping to guide treatment decisions.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
